STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Phase of Trial: Phase I
Latest Information Update: 30 May 2017
At a glance
- Drugs IGF-methotrexate (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms STM-02
- 07 Jun 2017 Biomarkers information updated
- 27 Apr 2017 Status changed from recruiting to completed.
- 01 Jun 2014 The study design presented at : 50th Annual Meeting of the American Society of Clinical Oncology.